• News
  • SAN DIEGO
  • BioTech

Perlan Therapeutics names Johnson president

Perlan Therapeutics Inc. announced Thursday the appointment of Sterling C. Johnson, to the positions of president and member of the board of directors.

Johnson will lead Perlan’s licensing, partnering, merger and acquisition, and strategic planning activities. He joins Perlan from Biota Holdings of Melbourne, Australia, where he served as vice president of global business development.

“Sterling’s extensive industry experience in business development, licensing, and corporate strategic planning puts us in a strong position to maximize the value of our optimization technology as well as our portfolio of drugs currently in development,” said Robert Jaffe, chairman of the board and president of Sorrento Ventures. “The addition of Sterling adds important breadth to our management team and reinforces our commitment to building strategic growth opportunities.”

Johnson's business career has included a range of sales, marketing and senior management assignments throughout the world. His management experience includes: president and CEO of Escalon Ophthalmics; president and CEO of Escalon Medical; president and CEO of Biota, Inc. Johnson’s expertise is in the establishment of new enterprises, business development and licensing, according to a Perlan statement. This includes negotiation and execution of more than 80 joint venture, merger, acquisition and license agreements in the U.S., Europe and Japan in the fields of medical devices, human pharmaceuticals, drug delivery, animal health and agri-chemicals.

Snapshot: Perlan Therapeutics

6310 Nancy Ridge Drive, Suite 102

San Diego, CA 92121

Phone: 858.622.0400

Fax: 858.622.0499

Web: http://www.perlan.com/

In Their Own Words

Perlan Therapeutics Inc. is an innovative developer of protein-based pharmaceuticals. The company’s proprietary technology platform is the basis for the development of high potency, cost-effective, protein-based therapeutics and diagnostic products. Executive, Position(s)

Sterling C. Johnson: President

Michele Yelmene: Exec. Dir. of Clinical and Regulatory Affairs

Robert Jaffe: Chairman

Company Type

Privately held.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Subscribe Today!